# IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma

> **NCT00242749** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 47 (—)

## Conditions studied

- Cancer of Head and Neck

## Interventions

- **DRUG:** Gefitinib, Cisplatin and Radiotherapy

## Key facts

- **NCT ID:** NCT00242749
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 47 (—)
- **Last updated:** 2009-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242749, "IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00242749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*